Navigation Links
Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Date:9/24/2008

REINACH, Switzerland, September 24 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced the completion of enrolment in the Phase II 'intravenous-to-oral' switch trial with oral iclaprim in patients with complicated Skin and Skin Structure Infections (cSSSI).

The trial was designed as a multi-centre, double-blind comparative study. Patients suffering from cSSSI received intravenous (IV) vancomycin for the first two days of treatment and were then randomised to either continue to receive IV vancomycin or to be switched to oral iclaprim for eight additional days. A total of 60 patients have been randomised for this study.

The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with IV vancomycin in the treatment of cSSSI. The primary endpoint is the clinical cure rate at the Test-of-Cure (TOC) visit. Secondary objectives include bacteriological outcome as well as safety and tolerability.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "The speed of enrolment in this Phase II trial surpassed our expectations. It again shows that an 'intravenous-to-oral' step-down therapy serves a medical need and could add significant value to intravenous iclaprim. Marketing applications for intravenous iclaprim have been filed in the U.S.A., the European Union and Canada. We will release the top-line data of this Phase II switch study in the coming months and subsequently determine the path ahead."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the USA. It focuses on the discovery, development and commercialisation of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product can
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... /PRNewswire-iReach/ -- Gateway Analytical announced today that they ... Annual Global Pharma Manufacturing Summit in ... The Global Pharma Manufacturing Summit offers a networking ... biologic pharmaceutical manufacturing. The conference is focused on ... such as the increasing pressure to grow and ...
(Date:8/28/2014)... Telik, Inc. (OTCQB: TELK), a clinical ... MabVax Therapeutics, Inc. on July 8, 2014, announced ... the development of its lead antibody program designated ... Company,s internally developed antibody discovery platform.  These preclinical ... based therapeutic and diagnostic products based on this ...
(Date:8/28/2014)... 2014  Rx Safes, Inc., the manufacturer of fingerprint ... waging a new war on drugs to reduce prescription ... More than 2,500 children a day experiment with ... are easily accessed from unsecured medicine cabinets, closets and drawers. ... streets, Rx Safes will address the new age drug ...
Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4Rx Safes, Inc. Announces New War On Drugs 2
... Study of Zalutumumab in Combination, With Radiotherapy ... COPENHAGEN, June 24 Genmab A/S (OMX: GEN),announced ... zalutumumab,(HuMax-EGFr(TM)) in combination with radiotherapy for the treatment of,advanced ... maximum of 36,patients who are ineligible for platinum based ...
... New Recommendations Address Presurgery and Pediatric Dilemmas, ... evidence-based guidelines,address the prevention and management of ... related to the routine use of,preventive therapies. ... issue of CHEST,the peer-reviewed journal of the ...
Cached Medicine Technology:Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 2Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 2Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 4
(Date:8/28/2014)... identify themselves as ,old, feel worse about their own ... value than younger age groups. , New research from ... and ill, across different countries: social status, age identification ... European Social Survey. Respondents, who were all aged 70 ... researchers found that those living in societies where older ...
(Date:8/28/2014)... New York (PRWEB) August 28, 2014 ... currently perceived with great interest among other healthcare industry ... to the high demand in vaccine with respect to ... highly in demand due to an improved understanding for ... across the United States. It has led to new ...
(Date:8/28/2014)... August 28, 2014 After more than ... Vitenas is excited to announce the opening of ... kind in any city, Mirror Mirror Beauty Boutique offers ... Situated on the corner of Richmond and Drexel near ... luxurious amenities, and cutting-edge technology in a private, easy ...
(Date:8/28/2014)... By Steven Reinberg ... -- Treating pre-cancerous skin spots with a type of light ... freezing the lesions with liquid nitrogen, a new study suggests. ... on the scalp and face of people with fair complexions ... review of prior research found that people who underwent the ...
(Date:8/28/2014)... Lansdale, pA (PRWEB) August 28, 2014 ... is now available throughout the world, with large ... such services. Since laboratories differ with regard to ... times, and costs, payers may struggle to find ... testing needs. To help clients sort through these ...
Breaking Medicine News(10 mins):Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 2Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 3Health News:Mirror Mirror Beauty Boutique to Welcome Its First Patients 2Health News: Light Therapy a Good Option for Pre-Cancerous Skin Lesions, Study Says 2Health News: Light Therapy a Good Option for Pre-Cancerous Skin Lesions, Study Says 3Health News:Hayes, Inc. Unveils Laboratory Comparison Tables for GTE Clients 2
... On the third anniversary,of Hurricane Katrina, with ... America,s Health (TFAH) issued the following statement, along,with ... to major,emergencies. TFAH also provides a set of ... the next potential health emergency based on,TFAH,s annual ...
... SEATTLE, Aug. 29 Attorneys representing consumers in ... illegally rigging the price of,virtually every prescription drug ... preparing for a trial set for December 1 ... http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO ), Attorney Steve W. Berman filed ...
... that Obama failed to address the issue, ... Convention Wednesday night, Former President Bill Clinton called,for ... in the,United States. In praising Presidential nominee Barack ... nation,s commendable global leadership in,an area in which ...
... normal development, mouse study finds , , FRIDAY, Aug. 29 (HealthDay ... short period in early pregnancy may cause fetal problems, suggest ... initial signs of fetal alcohol syndrome, which affects one in ... high upper lip, small eye openings, and a short nose. ...
... BRISBANE, Calif., Aug. 29 InterMune, Inc.,(Nasdaq: ITMN ... and,President of InterMune, will present at the Thomas Weisel ... 10:55 a.m. EDT., To access a live audio ... log on to the investor relations page of InterMune,s,corporate ...
... MYA Cosmetic Surgery Seems to be the Provider of Choice ... Will be Next?, Months of constant cameras, mirrors all ... can have a major impact on how you feel,about the ... has,become a reality. Upon leaving the house contestants may undoubtedly ...
Cached Medicine News:Health News:On the Third Anniversary of Hurricane Katrina; Trust for America's Health Questions State of National Emergency Preparedness 2Health News:On the Third Anniversary of Hurricane Katrina; Trust for America's Health Questions State of National Emergency Preparedness 3Health News:On the Third Anniversary of Hurricane Katrina; Trust for America's Health Questions State of National Emergency Preparedness 4Health News:Hagens Berman Sobol Shapiro: Attorneys Representing Consumers Prepare for $12 Billion RICO Trial Against McKesson for Alleged Drug Price Manipulation 2Health News:Hagens Berman Sobol Shapiro: Attorneys Representing Consumers Prepare for $12 Billion RICO Trial Against McKesson for Alleged Drug Price Manipulation 3Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 2Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 3Health News:Alcohol in Early Pregnancy May Prompt Fetal Cell Death 2Health News:MYA Makes Big Brother Stars Amazing! 2Health News:MYA Makes Big Brother Stars Amazing! 3
... contact lenses used for corneal refractive therapy, ... The patient wears the lenses overnight while ... the day, nearsightedness is corrected or greatly ... contact lenses apply slight pressure to the ...
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
... currently maintains a large number of mobile, ... in its rental fleet. The labs are ... to several years. The Cath Lab Leasing ... while replacing or upgrading existing equipment, initiating ...
... holmium laser combines excellent cutting, ablation ... bloodless procedures. It is also extremely ... bladder stones of all compositions, making ... Because its laser light is transmitted ...
Medicine Products: